WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition. Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription. “While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free. The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS. |
West Virginia GOP County Commissioners removed from office after arrest for skipping meetingsEthan Hawke and Maya Hawke on their Flannery O’Connor movie ‘Wildcat’26 Republican attorneys general sue to block Biden rule requiring background checks at gun showsEvan Mobley has huge block in final seconds as Cavaliers hold off Banchero, Magic 104George W. Bush's portraits of veterans are heading to Disney WorldColumbia University student journalists had an upTrump will speak at the Libertarian National Convention as he woos independent voters'Cursed' steamship that vanished in 1909 with 14 men aboard is finally discovered 115 years laterHollywood star Bill Murray rides the subway with fellow Cubs fans after watching Chicago's 3PSG defender Lucas Hernández injured in Champions League semifinal first leg at Dortmund